Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

FARAFARA Cure FA

Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia

BACKGROUND:

Erythropoietin (EPO) derivatives have been found to increase frataxin levels in Friedreich's ataxia (FRDA) in vitro. This multicenter, double-blind, placebo-controlled, phase II clinical trial aimed to evaluate the safety and tolerability of Lu AA24493 (carbamylated EPO; CEPO).

Read More: Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia


About the Author

Jen Farmer

Jen Farmer

Executive Director

SHARE

FacebookTwitterLinkedinShare on Google+
Event C.jpg

 

Archived in
  Scientific News


 

 

Tagged in
FARA Scientific News